IIT RESEARCH INSTITUTE - IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)
Key Details
Description
IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED)
Context & Analysis
On Dec 2, 2025, Department of Health and Human Services obligated $1,984,675.73 to IIT RESEARCH INSTITUTE for igf::ot::igf lfa-9 (mpges-1/5-lox inhibitor): preclinical studies to support a clinical trial, pop 9/17/18-9/16/2020 (up to 9/17/2021 if all optional tasks exercised). The award is classified under NAICS 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY and issued as a firm fixed price contract. Competition extent: full and open competition with 2 offers received. Performance is located in CHICAGO, IL. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541711 — related awards are listed below.
Contractor Information
Similar Awards
CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF
CERUS CORPORATION
$185.5M
THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF
MEDICINES COMPANY, THE
$98.1M
IGF::OT::IGF
JANSSEN VACCINES & PREVENTION B.V.
$48.9M
IGF::OT::IGF - DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
DNAE GROUP HOLDINGS LIMITED
$43.4M
AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES
AVITA MEDICAL AMERICAS, LLC
$40.8M
Stay Updated
Get notified about new opportunities matching your interests.